1. Home
  2. TGTX vs ASR Comparison

TGTX vs ASR Comparison

Compare TGTX & ASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.36

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Logo Grupo Aeroportuario del Sureste S.A. de C.V.

ASR

Grupo Aeroportuario del Sureste S.A. de C.V.

N/A

Current Price

$266.38

Market Cap

7.8B

ML Signal

N/A

Company Overview

Basic Information
Metric
TGTX
ASR
Founded
1993
1996
Country
United States
Mexico
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.8B
IPO Year
2008
2001

Fundamental Metrics

Financial Performance
Metric
TGTX
ASR
Price
$64.36
$266.38
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$69.43
★ $324.22
AVG Volume (30 Days)
★ 1.8M
41.3K
Earning Date
11-09-2026
10-22-2026
Dividend Yield
N/A
★ 3.71%
EPS Growth
★ 1746.67
N/A
EPS
★ 0.52
N/A
Revenue
★ $2,785,000.00
N/A
Revenue This Year
$61.95
$6.96
Revenue Next Year
$35.55
$23.46
P/E Ratio
$120.60
★ $18.58
Revenue Growth
N/A
★ N/A
52 Week Low
$26.76
$226.19
52 Week High
$68.03
$381.52

Technical Indicators

Market Signals
Indicator
TGTX
ASR
Relative Strength Index (RSI) 60.53 59.46
Support Level $52.12 $257.47
Resistance Level $63.60 $268.00
Average True Range (ATR) 3.52 5.30
MACD 0.14 0.36
Stochastic Oscillator 64.62 63.05

Price Performance

Historical Comparison
TGTX
ASR

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About ASR Grupo Aeroportuario del Sureste S.A. de C.V.

Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.

Share on Social Networks: